New York-based Pfizer Inc. (PFE) develops, manufactures, distributes, and sells biopharmaceutical products worldwide. The company provides medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health; biologics, small molecules, immunotherapies, biosimilars; and COVID-19.
Earlier this week, PFE and Valneva SE (VALN), a specialty French vaccine company, entered into an equity subscription agreement. As part of the agreement, PFE will invest $95 million for an 8.1% stake in VALN to further support the strategic Lyme partnership between the two companies.
